ArticleBlood advances2026
GVHD prophylaxis after cord blood transplantation in patients with high-risk AML: a nationwide Japanese cohort study.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mycophenolate mofetil-based graft-versus-host disease prophylaxis is associated with an increased risk of human herpesvirus 6B encephalitis after cord blood transplantation.Bone marrow transplantation · 2026Article
- Reconsidering GVHD prophylaxis in cord blood transplantation.Blood advances · 2026Article
Corrections and comments
- Commented on by
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractCord blood transplantation (CBT) is a curative option for patients with high-risk acute myeloid leukemia (AML), including therapy-related AML (t-AML). However, the optimal prophylaxis for graft-versus-host disease (GVHD) remains unclear. We conducted a nationwide, retrospective cohort study including 3222 adults with high-risk AML (t-AML and non-t-AML) who underwent their first CBT in Japan between 2010 and 2023. GVHD prophylaxis consisted of cyclosporine or tacrolimus combined with mycophenolate mofetil (CSP/TAC + MMF) or methotrexate (CSP/TAC + MTX). MMF regimens were associated with faster neutrophil engraftment than MTX regimens (P < .001). However, CSP/TAC + MMF showed significantly higher incidences of grades 2 to 4 acute GVHD (P < .001) and chronic GVHD (P < .001). Two-year transplant-related mortality and relapse rates were 26 to 38% and 41 to 46%, respectively. Overall survival and disease-free survival at 2 years were higher with MTX than with MMF (P < .001 and P = .003, respectively), indicating a modest survival advantage for MTX. Multivariable analysis identified older age (≥55 years), male sex, Karnofsky performance status <80, higher hematopoietic cell transplantation-specific comorbidity index, and no remission at transplantation as adverse prognostic factors. Notably, MMF use was associated with an increased risk of human herpesvirus 6 encephalitis. Both CSP/TAC + MMF and CSP/TAC + MTX regimens support successful CBT in high-risk AML. Although MMF accelerates engraftment, this benefit is offset by greater GVHD and viral complications. These real-world, nationwide data highlight the need to individualize GVHD prophylaxis based on patient and transplant characteristics and provide essential benchmarks for future multicenter prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.